Overview

Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer

Status:
Unknown status
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
Multi-center, non randomised, open label, non controlled pilot study. Evaluating the treatment of bevacizumab in association with pre-operative chemotherapy, followed by surgery, adjuvant chemotherapy and radiotherapy in Patients with inflammatory breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Association Tunisienne de lutte Contre le Cancer
Collaborators:
Hoffmann-La Roche
Sanofi
Treatments:
Bevacizumab
Cyclophosphamide
Docetaxel
Epirubicin
Fluorouracil
Trastuzumab